Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Liabilities and Shareholders Equity: 2010-2025

Historic Liabilities and Shareholders Equity for BIO-TECHNE (TECH) over the last 16 years, with Sep 2025 value amounting to $2.5 billion.

  • BIO-TECHNE's Liabilities and Shareholders Equity fell 7.67% to $2.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 billion, marking a year-over-year decrease of 4.53%. This contributed to the annual value of $2.6 billion for FY2025, which is 5.40% down from last year.
  • Per BIO-TECHNE's latest filing, its Liabilities and Shareholders Equity stood at $2.5 billion for Q3 2025, which was down 1.24% from $2.6 billion recorded in Q2 2025.
  • In the past 5 years, BIO-TECHNE's Liabilities and Shareholders Equity registered a high of $2.8 billion during Q3 2023, and its lowest value of $2.1 billion during Q1 2021.
  • Its 3-year average for Liabilities and Shareholders Equity is $2.7 billion, with a median of $2.7 billion in 2024.
  • Per our database at Business Quant, BIO-TECHNE's Liabilities and Shareholders Equity increased by 17.21% in 2023 and then decreased by 7.67% in 2025.
  • Quarterly analysis of 5 years shows BIO-TECHNE's Liabilities and Shareholders Equity stood at $2.3 billion in 2021, then climbed by 2.54% to $2.4 billion in 2022, then increased by 15.54% to $2.7 billion in 2023, then dropped by 2.21% to $2.7 billion in 2024, then decreased by 7.67% to $2.5 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $2.5 billion for Q3 2025, versus $2.6 billion for Q2 2025 and $2.6 billion for Q1 2025.